Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer

Hiroshi Miyata, Masahiko Yano, Takushi Yasuda, Rie Hamano, Makoto Yamasaki, Eihou Hou, Masaaki Motoori, Osamu Shiraishi, Koji Tanaka, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background & aims: Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer. Methods: Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy. Results: Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly. Conclusions: Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers. The clinical trial registration number: UMIN000004483.

Original languageEnglish
Pages (from-to)330-336
Number of pages7
JournalClinical Nutrition
Volume31
Issue number3
DOIs
Publication statusPublished - Jun 1 2012
Externally publishedYes

Fingerprint

Enteral Nutrition
Esophageal Neoplasms
Drug Therapy
Leukopenia
Neutropenia
Clinical Studies
Neoplasms
Lymphopenia
Body Weight Changes
National Cancer Institute (U.S.)
Incidence
Serum Albumin
Fluorouracil
Thrombocytopenia
Doxorubicin
Cisplatin
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine

Cite this

Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. / Miyata, Hiroshi; Yano, Masahiko; Yasuda, Takushi; Hamano, Rie; Yamasaki, Makoto; Hou, Eihou; Motoori, Masaaki; Shiraishi, Osamu; Tanaka, Koji; Mori, Masaki; Doki, Yuichiro.

In: Clinical Nutrition, Vol. 31, No. 3, 01.06.2012, p. 330-336.

Research output: Contribution to journalArticle

Miyata, Hiroshi ; Yano, Masahiko ; Yasuda, Takushi ; Hamano, Rie ; Yamasaki, Makoto ; Hou, Eihou ; Motoori, Masaaki ; Shiraishi, Osamu ; Tanaka, Koji ; Mori, Masaki ; Doki, Yuichiro. / Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. In: Clinical Nutrition. 2012 ; Vol. 31, No. 3. pp. 330-336.
@article{7fae03a490db44a6bedaba6ec534243a,
title = "Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer",
abstract = "Background & aims: Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer. Methods: Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy. Results: Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51{\%}, PN: 55{\%}, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17{\%} vs 41{\%}, p = 0.011, neutropenia: 36{\%} vs 66{\%}, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly. Conclusions: Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers. The clinical trial registration number: UMIN000004483.",
author = "Hiroshi Miyata and Masahiko Yano and Takushi Yasuda and Rie Hamano and Makoto Yamasaki and Eihou Hou and Masaaki Motoori and Osamu Shiraishi and Koji Tanaka and Masaki Mori and Yuichiro Doki",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.clnu.2011.11.002",
language = "English",
volume = "31",
pages = "330--336",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer

AU - Miyata, Hiroshi

AU - Yano, Masahiko

AU - Yasuda, Takushi

AU - Hamano, Rie

AU - Yamasaki, Makoto

AU - Hou, Eihou

AU - Motoori, Masaaki

AU - Shiraishi, Osamu

AU - Tanaka, Koji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background & aims: Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer. Methods: Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy. Results: Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly. Conclusions: Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers. The clinical trial registration number: UMIN000004483.

AB - Background & aims: Enteral nutrition (EN) is provided for patients with cancer. However, Little is known about the clinical efficacy of EN support during chemotherapy in patients with cancer. Methods: Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n = 47) or PN (n = 44) at random. The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy. Results: Total and dietary intake calories during chemotherapy were equal in the two groups. There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups. There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886). Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005). Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly. Conclusions: Compared with PN support, EN support during neoadjuvant chemotherapy reduced the incidence of chemotherapy-related hematological toxicities in patients with esophageal cancers. The clinical trial registration number: UMIN000004483.

UR - http://www.scopus.com/inward/record.url?scp=84861345919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861345919&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2011.11.002

DO - 10.1016/j.clnu.2011.11.002

M3 - Article

C2 - 22169459

AN - SCOPUS:84861345919

VL - 31

SP - 330

EP - 336

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 3

ER -